Respiratory syncytial virus (RSV) is the most frequent cause of lower respiratory disease and hospitalization in infants, but there is currently no vaccine available to prevent or treat RSV disease. Researchers at Nationwide Children’s Hospital and The Ohio State University have developed a novel method for designing RSV vaccines using a Vesicular Stomatitis Virus (VSV) vector. VSV is attenuated in humans, so it can infect people and express inserted genes without causing disease. Additionally, VSV grows to high titers in culture, allowing for efficient vaccine production.